source
- Novo presents low-dose CagriSema data showing competitiveness ahead of approval decisionNovo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…
- White House considers executive order to politicize NIH grant approvalsSenior officials met in the Oval Office on Friday to discuss an executive order that would establish an external panel with authority to reject NIH grant applications. The meeting, reported by The…